MYRTLE BEACH, SC / ACCESS Newswire / December 19, 2025 / Coastal Carolina Bancshares, Inc. (OTCQX:CCNB) (the "Company" or "CCNB"), parent company of Coastal Carolina National Bank, announced today that it has entered into Securities Purchase Agreements providing for the issuance of $15 million in common equity at a price of $12.50 per share to institutional and certain accredited investors. The Company intends to use the proceeds from the common equity issuance for general corporate purposes, including stre ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES MONTREAL, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Morocco Strategic Minerals Corporation. (TSXV: MCC) ("MCC" or the "Corporation") announce the closing of a non-brokered private placement, raising total gross proceeds of $600,000 through the issuance of 6,000,000 units of the Corporation ("Units") at a price of $0.10 per Unit (the "Offering"). Each Unit consists in one common share of the Corporation (a “Common Share”) and on ...

VANCOUVER, British Columbia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Canadian GoldCamps Corp. (CSE: CAMP) (OTC: SMATF) (FSE: A68) (the “Company”) is pleased to announce management and board changes, a non-brokered private placement financing to raise up to $1 million and a binding letter of intent (the “LOI”) in respect of a proposed option agreement to acquire two gold exploration projects in Québec from Stelmine Canada Ltd. (TSXV: STH) (“Stelmine”). MANAGEMENT AND BOARD CHANGES The Company announces that Mr. Ge ...

VANCOUVER, BRITISH COLUMBIA, December 18, 2025 – TheNewswire - (TSXV: PINN, OTC: PSGCF, Frankfurt: P9J) – Pinnacle Silver and Gold Corp. ("Pinnacle" or the “Company") is pleased to announce that it has closed a first tranche of the non-brokered private placement announced on November 25, 2025 (the “Offering”) for gross proceeds of $1,067,532.94.  The first tranche consisted of 7,268,171 units (the "Units") with each Unit, priced at $0.14, comprising one common share (“Share”) in the capital of the Company ...

Edmonton, Alberta--(Newsfile Corp. - December 18, 2025) - Grizzly Discoveries Inc. (TSXV: GZD) (FSE: G6H) (OTCQB: GZDIF) ("Grizzly" or the "Company") announces that, on December 17, 2025, it closed on the sale of 8,000,000 FT Units, at $0.03 per FT Unit, for gross proceeds of $240,000 as an initial tranche of a non-brokered private placement originally announced on November 25, 2025 (the "Offering").The Offering consists of up to 8,333,333 Units and up to 25,000,000 of any combination of Units and FT Units ...

DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the ...

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - GoldQuest Mining Corp. (TSXV: GQC) (OTCQX: GDQMF) ("GoldQuest" or the "Company") is pleased to announce that due to significant interest, the Company intends to increase the size of its previously announced non-brokered private placement (the "Private Placement"). The Private Placement will now be comprised of an aggregate of up to 34,710,743 units of the Company (the "Units") at a price of $1.21 per Unit, for aggregate gross proceeds of u ...

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Legend Power Systems Inc. (TSXV: LPS) (OTCQB: LPSIF) ("Legend Power" or the "Company"), announces a non-brokered private placement of a minimum of 11,111,111 units and up to a maximum of 14,186,000 units of the Company (each, a "Unit") at a price of CAD$0.12 per Unit for aggregate gross proceeds of a minimum of CAD$1,333,333 and up to a maximum of CAD$1,702,320 (the "Offering"). The Offering is being completed pursuant to the amendments to ...

公司状态与监管更新 - 公司即将在AMF和TSX Venture Exchange审查后恢复上市交易 [1] - 公司自2024年8月21日后未召开年度股东大会 不符合交易所政策 作为恢复上市条件 公司承诺在90天内召开 股东大会定于2026年3月6日上午10点通过Microsoft Teams公开举行 [1] 资产出售交易 - 公司于2025年9月18日接受Multi-Ressources Boréal的收购要约 出售其位于Abitibi地区Duplessis的Duplessis-Agar和Duplessis-Mountain资产 交易总价值为25万加元 全部以现金支付 分三期在最终协议签署后最多30天内付清 [1] - 该交易不构成关联方交易 标的资产无任何诉讼或产权负担 但存在一项现有的1% NSR特许权使用费 资产包含总共16个采矿权 公司将为买方提供所有相关文件和技术数据 交易不涉及任何中介费用 [1] - 该交易需完成全面尽职调查并获得所有适用的监管批准 [1] 融资活动更正 - 公司对2025年3月14日关于私募融资结束的新闻稿进行更正 因一名投资者退出 最终融资额为1.5万加元 [1] - 融资以每单位0.045加元的价格向合格投资者发行 每单位包含1股普通股和1份认股权证 权证允许持有人在融资结束后12个月内以每股0.07加元的价格购买1股普通股 总共发行333,334个单位 [1] - 本次融资无内部人士参与 未产生中介费用 所发行证券有至少四个月加一天的持有期 融资所得将用于各种营运资金需求 交易尚需获得TSX Venture Exchange的最终接受 [1] 做市服务安排 - 公司于2024年10月9日聘请Venture Liquidity Providers Inc. 启动做市服务 以协助维持公司普通股的有序交易市场 服务通过注册经纪商W.D. Latimer Co. Ltd.进行 [1] - 公司同意向VLP每月支付5,000加元 初始期限为3个月 之后可续期1个月 该协议于2024年10月9日签署 并于2025年1月10日终止 [1] - 公司还同意以492,500份认股权证 行权价为0.09加元 换取VLP的咨询 推广和营销服务 所有这些权证已于2025年10月9日到期未行权 [1] 财务状况与资本计划 - 截至2025年5月31日的三个月中期财务报表显示 公司营运资金缺口为350,203加元 [1] - 在过去几周出售其Duplessis Agar和Duplessis-Mountain资产后 公司已支付大部分债权人款项 [1] - 公司最大的应付账款债权人Orbit Garant 欠款18万加元 该公司是一家钻探公司 Goldflare的一位董事会成员Pierre Alexandre是其CEO 如果公司财务状况允许且公司股票恢复交易 Orbit Garant愿意接受以Goldflare股份支付 [1] - 公司计划在恢复上市后 通过流通股和普通股私募融资来筹集资金 公司认为所有这些选项结合起来将使其满足最低CLR营运资金要求 [1]

融资事件概览 - 公司Kalaris Therapeutics宣布与一组机构投资者达成证券购买协议 通过私募配售筹集总额约5000万美元的总收益[1] - 私募配售预计于2025年12月19日左右完成 取决于惯例成交条件的满足[3] 融资结构与条款 - 私募配售包括以每股10美元的价格出售420万股普通股[3] - 同时向部分投资者出售可购买80万股普通股的预融资权证 每份权证价格为9.9999美元[3] - 每份预融资权证的行权价为每股0.0001美元 发行后可随时行权 直至全部行使完毕[3] - 本次配售证券的每股定价较公司股票在纳斯达克全球市场前五个交易日的收盘价存在溢价[3] 投资者构成 - 参与方包括新老投资者 例如ADAR1 Capital Management、Coastlands Capital、Invus、RTW Investments、Samsara BioCapital、Woodline Partners LP等[2] 资金用途与财务规划 - 公司计划将本次私募的净收益与现有现金及短期投资一起 用于推进主要候选药物TH103用于新生血管性年龄相关性黄斑变性的临床开发[4] - 资金也将用于营运资本及其他一般公司用途[4] - 基于当前运营计划 公司预计现有资金及本次私募净收益将足以支持其运营至2027年第三季度[4] 交易中介与法律安排 - 摩根士丹利和Leerink Partners担任本次私募的牵头配售代理 William Blair也担任配售代理[5] - 本次发行的证券未根据《证券法》注册 但公司与投资者同意签订注册权协议 公司将向美国证券交易委员会提交注册声明以注册这些证券的转售[6] 公司背景 - Kalaris Therapeutics是一家临床阶段的生物制药公司 专注于开发治疗常见视网膜疾病的疗法[8] - 公司由著名科学家Napoleone Ferrara博士创立 其开创性研究推动了抗VEGF疗法的开发[8]